RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26

Lakefront Biotherapeutics Sponsored ADR

Lakefront Biotherapeutics Sponsored ADR

LKFT

0.00

RBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ: LKFT) with a Sector Perform and lowers the price target from $28 to $26.